AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations ...

Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

TAT and several other markers demonstrated an ability to predict the development of venous thromboembolism in patients with cervical cancer.

The study revealed the risk of developing venous thromboembolisms from various types of synthetic hormones, providing ...

Cancer pts who have undergone major surgery or had previous VTE should continue prophylaxis with an LMWH after discharge for up to 28 days. a CNS = central nervous system, GI = gastrointestinal ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

“However, let’s say you have a patient with advanced breast cancer and you calculate their clinical risk for VTE using something like a Khorana score, and they’re high risk, so you’re ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...